BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of “Moderate Buy” by Brokerages

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has earned a consensus rating of “Moderate Buy” from the twenty-five analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $88.6087.

BMRN has been the topic of a number of recent analyst reports. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $66.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 28th. Wolfe Research reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Stifel Nicolaus reiterated a “hold” rating and issued a $61.00 target price (down from $73.00) on shares of BioMarin Pharmaceutical in a report on Thursday, November 6th. HC Wainwright lowered their price objective on shares of BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating for the company in a research note on Monday, October 27th. Finally, JPMorgan Chase & Co. increased their price objective on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th.

BioMarin Pharmaceutical Stock Down 0.9%

Shares of BMRN opened at $53.82 on Friday. The stock has a market capitalization of $10.34 billion, a price-to-earnings ratio of 20.23, a PEG ratio of 0.91 and a beta of 0.30. BioMarin Pharmaceutical has a 52 week low of $50.76 and a 52 week high of $73.51. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.10 and a current ratio of 4.83. The stock has a fifty day moving average of $53.87 and a 200-day moving average of $55.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.20). BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The firm had revenue of $776.13 million for the quarter, compared to the consensus estimate of $782.42 million. During the same quarter last year, the firm posted $0.91 earnings per share. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. As a group, sell-side analysts anticipate that BioMarin Pharmaceutical will post 3.15 earnings per share for the current fiscal year.

Institutional Trading of BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC lifted its stake in shares of BioMarin Pharmaceutical by 90.7% in the second quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock valued at $306,429,000 after buying an additional 2,654,768 shares in the last quarter. Nuveen LLC purchased a new stake in shares of BioMarin Pharmaceutical in the first quarter worth approximately $184,475,000. Capital Research Global Investors boosted its position in shares of BioMarin Pharmaceutical by 547.5% during the third quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock valued at $137,436,000 after buying an additional 2,145,717 shares during the last quarter. Norges Bank purchased a new stake in BioMarin Pharmaceutical in the 2nd quarter valued at $112,352,000. Finally, Viking Global Investors LP grew its stake in shares of BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.